[Comparative study of the pharmacological and clinical effects of clorimipramine and metaprimine (19560 R.P.)].
Although its pharmacology is virtually identical with that of the tricyclic antidepressants, metapramine (19560 R.P.), i.e. methyl-5 methylamino-10 dihydro-10, 11 dibenzo (b,f) azepine, differs biochemically from the tricyclics in that it markedly enhances the turnover of norepinephrine without notably inhibiting the re-uptake of this amine. Differences in the therapeutic effects of metapramine and clorimipramine have been investigated in a double-blind clinical test. The possible relationship between these differences and the biochemistry of both compounds is discussed in terms of the monoaminergic hypotheses.
D000328:Adult; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D002997:Clomipramine / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy* / Q000201:enzymology; D003984:Dibenzazepines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008995:Monoamine Oxidase / Q000378:metabolism
D000929:Antidepressive Agents, Tricyclic; D003984:Dibenzazepines; D008995:Monoamine Oxidase; D002997:Clomipramine
Essai de corrélation pharmaco-clinique clorimipramine-métapramine (19560-R.P.)